Search PubMed⌕ Search

Biomedical subjects

L Wallentin

Publications and source records attributed to L Wallentin.

At least 145 records · Page 8Linked to original sources
PubMed1984

Lipoprotein abnormalities in patients with early primary biliary cirrhosis.

In twelve females with early forms of primary biliary cirrhosis (PBC) serum lipoproteins, the intravenous fat tolerance test ( IVFTT ) and the lecithin: cholesterol acyl transferase (LCAT) rate were determined and compared to healthy controls. The cholestatic LDL (LP-X) test was negative in all cases. PBC patients had lower very low density lipoprotein TG concentrations than controls and had levels of (high-density lipoprotein) HDL-TG, -cholesterol and -phospholipids that were about 50% higher than in controls. In PBC the HDL2-cholesterol concentration was double but the HDL3-cholesterol concentration was 60% of control values (P less than 0.001 for both). The LCAT rate and the IVFTT value did not differ between the groups. A typical finding on agarose gel electrophoresis was the appearance of a slow-moving alpha-band. Several interpretations of these results are possible. In PBC the hepatic lipase activity may be impaired leading to a shift of the HDL2/HDL3 relation. The transport of HDL2 to the liver lipase site may also be affected and HDL3 production reduced due to malabsorption in the intestine.

Adult↗
PubMed1984

Plasma lipoproteins during and after danazol treatment.

Twelve women with pelvic endometriosis were treated with danazol, at a dose of 200 mg three times daily, over a 24-week period. The concentrations of cholesterol and triglycerides were determined in plasma and in the lipoprotein fractions. After only 2 weeks the mean high density lipoprotein (HDL) cholesterol had already decreased by 49% and 6 weeks later the reduction was 59%. The low density lipoprotein (LDL) cholesterol concentration increased by 14% after 2 weeks and by 34% after 8 weeks. The triglycerides increased by 20% after 2 weeks. Eight weeks after cessation of treatment the lipoprotein fractions had returned to the pretreatment levels.

Danazol↗
PubMed1983

L-norgestrel and progesterone have different influences on plasma lipoproteins.

Twenty-six postmenopausal women who had been on cutaneous oestradiol treatment for 3-6 months were given either 120 micrograms of 1-norgestrel (n = 13) or 300 mg of progesterone (n = 13) sequentially for another 6 months. The concentrations of cholesterol, phospholipids and triglycerides were determined in plasma and in the HDL, HDL2, HDL3, LDL and VLDL fractions before and after one, three and six cycles of progestin treatment. Already after 11 days on 1-norgestrel, the mean HDL cholesterol and the mean HDL phospholipid concentrations were reduced by 15%. The reduction of the HDL-lipids was mainly confined to the HDL2 fraction which was decreased by 25-30%. L-norgestrel also reduced the mean TG concentration both in the VLDL and the combined LDL + HDL fractions. Progesterone gave only minor changes of the plasma lipids and lipoproteins. Reduced HDL, especially HDL2, concentration, as induced by 1-norgestrel, might increase the risk for ischaemic heart disease. Therefore, it seems that, as regards the effects on the lipoproteins, progesterone might be more suitable than the 19-nortestosterone derivative 1-norgestrel for postmenopausal sequential hormonal therapy.

Cholesterol↗
PubMed1983

High density lipoprotein subfractions during oral and cutaneous administration of 17 beta-estradiol to menopausal women.

Thirty eight women with menopausal vasomotor symptoms were randomly allocated to 6 months treatment with either 2-4 mg micronized estradiol given orally or 3 mg estradiol applied cutaneously. The concentrations of cholesterol (C) and phospholipids (PL) were determined in high density lipoprotein (HDL) and its subfractions HDL2 and HDL3 twice before treatment and after 2, 4, and 6 months of medication. Oral estradiol increased the C and PL concentration in the HDL2 fraction in a dose-dependent way. With 2 mg estradiol orally the HDL3 fraction did not change, whereas 4 mg estradiol orally increased the C and PL concentrations in the HDL3 fraction. Cutaneous treatment with estradiol did not influence the lipid level in HDL or its subfractions. It is concluded that the rise of HDL during estrogen treatment is mainly caused by an elevation of the HDL2 fraction. Furthermore, the route of administration of estrogens has a profound influence on the metabolism of the HDL subfractions.

Administration, Oral↗
PubMed1982

Lipoproteins during oral and cutaneous administration of oestradiol-17 beta to menopausal women.

Thirty-eight post-menopausal women were randomly allocated to substitution treatment with either oestradiol-17 beta orally (2-4 mg) or cutaneously (3 mg). The concentrations of cholesterol (C), triglycerides (TG) and phospholipids were determined in the high density lipoprotein (HDL)-, the low density lipoprotein (LDL)- and the very low density lipoprotein (VLDL)- fractions twice before medication and after 2, 4 and 6 months of treatment. Both treatments gave satisfactory clinical results. Oral doses increased the HDL and decreased the LDL thus raising the HDL-C/LDL-C ratio. The higher oral dose also increased the TG concentration. Cutaneous oestradiol gave only minimal changes of the lipoproteins. The lipoprotein changes observed during treatment with oral oestradiol might reduce the risk for atherosclerotic disease. Therefore, from a lipoprotein point of view, oral oestradiol treatment probably could be considered beneficial. The cutaneous oestradiol treatment had comparable clinical effects without any influence on the lipoprotein pattern.

Administration, Oral↗
PubMed1982

Effects of the estrogenicity of levonorgestrel/ethinylestradiol combinations of the lipoprotein status.

Ninety-eight women seeking contraceptive advice were randomly allocated to 6 months of treatment with one of the following four combinations of ethinylestradiol (EE) and levonorgestrel (NG): 20/250, 30/250, 30/150, and the so-called triphasic drug. The EE/NG ratios were 0.08, 0.12, 0.20 and 0.36 respectively. Blood lipids, HDL-cholesterol and sex hormone binding globulin (SHBG) were determined twice before treatment and after 1, 3 and 6 months of medication. Plasma triglyceride levels were moderately elevated in all groups, with the highest increase in the women taking the triphasic drug. The HDL-cholesterol and HDL-cholesterol to cholesterol ratios were both markedly reduced, by 20/250 and 30/250, while 30/150 and the triphasic drug caused only minor reductions. The mean change in HDL-cholesterol showed a good correlation with the mean changes of SHBG (r = 0.916) and with the EE/NG ratios (r = 0.979). It is concluded that both SHBG and the EE/NG ratio may be used as an index of the estrogenicity of a combined oral contraceptive drug. As reduced HDL-cholestrol levels and HDL-cholesterol to cholesterol ratios have been shown to be directly correlated to the risk of developing ischemic cardiovascular disease it would seem important that the estrogenicity of such a drug should be sufficiently high.

Cholesterol↗
PubMed1982

The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.

The peripheral plasma concentrations of testosterone, luteinising hormone (LH) and follicle stimulating hormone (FSH) were determined in 46 patients (age 51-86 years) with cytologically confirmed prostatic carcinoma. Treatment consisted of subcapsular orchidectomy (15 cases) or estrogen medication (16 cases) or cyproterone acetate (15 cases). The determinations were made before and 2 weeks and 2 months after treatment was initiated. No correlation was found between the pretreatment levels of testosterone and gonadotrophins and the local extent of the primary tumor or the degree of malignancy. Nor was there any correlation between hormonal level, presence of metastases or patient age. Orchidectomy and estrogen medication both resulted in very low plasma testosterone levels, corresponding to 15% of the pretreatment values. This proportion was 28% in the group treated with cyproterone acetate. Orchidectomy was followed by significant increase in the levels of LH and FSH. Estrogen treatment resulted in suppression of the LH levels to 40% and of FSH to 14% of the pretreatment values. The corresponding decreases in response to cyproterone acetate were 65 and 35%. The results indicate that reduction in gonadotrophin secretion is the primary mechanism in the lowering of testosterone levels produced by treatment with estrogens or cyproterone acetate.

Aged↗
PubMed1982

[Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].

16 patients with advanced carcinoma of the prostate were studied in a prospective trial during treatment with oestrogens. Changes in plasma levels of gonadotropins (LH and FSH) and testosterone as well as salt-water balance, antithrombin III, fibrinolytic activity, plasma lipoproteins known to influence the risk of cardiovascular complications, were recorded during the initial 2 months. The plasma testosterone, LH and FSH concentrations were suppressed. The plasma volume was increased and the plasma albumin concentration was decreased. The antithrombin III concentration and the tissue fibrinolytic activity were decreased. The low density lipoprotein (LDL) level decreased and the high density lipoprotein (HDL) level increased. The recorded changes of cardiovascular risk factors indicate that the risk of water retention and thereby congestive heart failure and the risk for thromboembolic disease are increased during oestrogen treatment. The changes in lipoproteins with a marked elevation of the HDL/LDL ratio are thought to retard the development of atherosclerosis.

Aged↗
PubMed1981

HDL3 and HDL2 determination by a combined ultracentrifugation and precipitation procedure.

The aim of the present study was to evaluate a method to separate lipoproteins by ultracentrifugation simultaneously at density 1.006 and 1.125. This procedure combined with heparin-MnCl2 precipitation would facilitate the simultaneous determination of lipid levels of high density lipoproteins (HDL) and its main subfractions (HDL2 and HDL3, including very high density lipoproteins (VHDL)) and of very low (VLDL) and low density lipoprotein (LDL) fractions. Centrifugation at 105 500 X g (mean) for 24 h in a Beckman L5-50 ultracentrifuge with a Ti50 rotor seemed to give an adequate separation. The correlation coefficients for duplicate samples were 0.95 and 0.96 for HDL3-cholesterol and HDL3-phospholipids, respectively. The error of the method for HDL, HDL2 and HDL3 lipids was around half that of the intra-individual variation and comparable to the results for determination of conventional lipoprotein fractions. Therefore the suggested method seems applicable for evaluation of HDL2 and HDL3 levels in selected clinical material.

Chlorides↗
PubMed1981

The effects of orchiectomy, oestrogens and cyproterone-acetate on the antithrombin-III concentration in carcinoma of the prostate.

The incidence of thromboembolic complications is increased in patients with oestrogen-treated prostatic carcinoma. Because reduced antithrombin-III (AT-III) levels are associated with increased risk of thromboembolism we have determined AT-III concentrations during oestrogen therapy and other treatments. Forty-six patients with carcinoma of the prostate were allocated to either treatment with subcapsular orchiectomy, oestrogen administration, or cyproterone acetate, AT-III was determined before treatment, at 2 weeks and 2 months later. During oestrogen therapy there was a significant reduction in AT-III to 77% of the base-line value. No significant changes were found after orchiectomy. During cyproterone-acetate treatment there was a slight but significant increase in AT-III at 2 months. The reduction in AT-III could indicate an increased risk of thromboembolism during oestrogen treatment of patients with carcinoma of the prostate. On the other hand, the unchanged AT-III levels after orchiectomy and the increased levels during cyproterone acetate therapy could mean that the risk of thromboembolism is less with these two forms of treatment.

Aged↗
PubMed1981

Lipoprotein changes may be minimized by proper composition of a combined oral contraceptive.

Lipids, high-density lipoprotein (HDL) cholesterol, and sex hormone-binding globulin (SHBG) were determined in 98 women treated with combined oral contraceptives containing ethinylestradiol (EE) and levonorgestrel (NG) in the following combinations: 20/250, 30/250, 30/150, and a so-called three-phase drug. The EE/NG ratios were 0.08, 0.12, 0.20, and 0.35, respectively. The HDL cholesterol and the HDL cholesterol to cholesterol ratios were markedly reduced by 20/250 and 30/250, whereas 30/150 and the three-phase drug caused only minor reductions. The mean change in HDL cholesterol showed a good correlation with the mean changes in SHBG (r = 0.916) and with the EE/NG ratios (r = 0.979). It is concluded that SHBG may be used as an index of estrogenicity of a combined oral contraceptive agent and that EE and NG may be balanced in such a way that undesirable effects on lipid metabolism are minimized.

Adolescent↗
PubMed1981

Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma.

The incidence of cardiovascular disease is lower in women than in men, but is raised in men with prostatic cancer treated with estrogens. Changes of the plasma lipoproteins are related to the development of ischaemic cardiovascular disease and can be brought about by hormonal treatment. We have therefore studied plasma lipoproteins during estrogen treatment and after orchidectomy. 16 patients with prostatic carcinoma were treated with ethinyl estradiol daily by mouth and polyestradiol phosphate intramuscularly once a month. 15 other patients were treated by bilateral orchidectomy. Cholesterol (C), triglyceride (TG), and phospholipid (PL) concentrations in plasma and in the very low density (VLDL), low density (LDL) and high density lipoprotein (HDL) fractions were determined before starting treatment and 2 weeks and 8 weeks later. In the estrogen treated group the mean plasma C concentration decreased by 14 and 10%, while the mean HLD-C increased by 23 and 53%, and the mean LDL-C decreased by 24 and 25% at 2 and 8 weeks respectively. The mean PL concentration in HDL increased by 36 and 79% while that in LDL decreased by 12 and 18%. The mean plasma TG concentration was increased by 36 and 46%, mainly reflecting a rise of TG in the HDL-LDL fraction. Orchidectomy created only slight changes of plasma lipids. After 8 weeks the mean C concentration in plasma was raised by 10% and the mean PL concentration by 11%, owing to a 13% rise in the mean HDL-PL level. The changes in plasma lipoprotein pattern created by high doses of estrogens are mainly thought to protect against the development of atherosclerosis. The slight changes that take place after orchidectomy can hardly affect the incidence of cardiovascular disease.

Aged↗
PubMed1981

High density lipoprotein and other lipoproteins in normolipidaemic and hypertriglyceridaemic (type IV) men with coronary artery disease.

The aim was to investigate whether a low concentration of high density lipoprotein (HDL) may be used as a risk indicator in normolipidaemic (n.l.) subjects, and whether a reduced HDL concentration constitutes an additional risk factor in hyperlipoproteinaemia. Eighty-two men with angiographically documented coronary artery disease (CAD) were studied. The majority of the CAD men was either n.l. (n = 38) or had type IV hyperlipoproteinaemia (n = 22). These two groups were compared separately to one group of healthy n.l. subjects (n = 44), and one group of healthy subjects with type IV hyperlipoproteinaemia (n = 29). In about 50% of n.l. CAD men the HDL-cholesterol (HDL-C) was lower than the 15th percentile (0.90 mmol/l) of n.l. controls, and about 65% of n.l. CAD men had ratios of HDL-C/total plasma cholesterol (C) lower than 0.17, the 15th percentile of n.l. controls. Almost all type IV subjects had reduced HDL-C levels and decreased ratios of HDL-C/C, whether they had obvious CAD or not. Thus, in normolipidaemia, but not in type IV hyperlipoproteinaemia, a low HDL-C level may be used as an additional risk factor for CAD development.

Adult↗
PubMed1981

Effects of oestrogens, orchidectomy and cyproterone acetate on salt and water metabolism in carcinoma of the prostate.

Salt and water metabolism was investigated during treatment with oestrogens and with cyproterone acetate and after orchidectomy in 46 patients. An increase in plasma volume was noted during oestrogen treatment and a slight transitory rise in plasma volume was also seen after orchidectomy. During cyproterone acetate therapy there was a reduction of body weight and a transitory increase in 24-hour urine volume and urinary sodium excretion. The increase in plasma volume during oestrogen treatment might tax the circulatory capacity. Cyproterone acetate treatment does not change the salt-water balance or the plasma volume in such a way that the risk of congestive heart failure could be increased.

Aged↗
PubMed1981

Lipoproteins and cholesterol esterification rate in men and women with hypercholesterolaemia of type IIa.

The purpose of this study was to investigate sexual differences regarding lipoprotein concentrations and compositions, and the cholesterol esterification rate in subjects with type IIa hypercholesterolaemia. Twenty men and 33 women with type IIa hyperlipoproteinaemia, asymptomatic as regards ischaemic heart disease were investigated. Total cholesterol (TC), triglycerides (TG) and phospholipids (PL) were measured in plasma and in the very-low-density (VLDL), low-density (LDL) and high-density lipoprotein (HDL) fractions. The cholesterol esterification rate was determined in plasma in vitro. In comparison with the male group the females had higher concentrations of TC and PL in the HDL, leading to higher ratios of HDL-TC/LDL-TC and HDL-PL/LDL-Pl in the females group. The cholesterol esterification rates were equal in the sexes. However, relations between the cholesterol esterification rates and lipoprotein concentrations and between cholesterol esterification rates and overweight were not equal in the sexes. The higher HDL-TC concentration and HDL-TC/DL-TC ratio in women than in men with type IIa might partly explain the lower female morbidity in cardiovascular disease.

Adult↗